Impact of a Pharmacist-Managed Telemedicine Pharmacotherapy Clinic in the Era of COVID-19

Abstract

Purpose: Telemedicine has been essential during the coronavirus disease 2019 (COVID-19) pandemic. In March 2020, pharmacist-led chronic disease state management services at our family care centers and primary care clinics were converted to telemedicine. This study aimed to determine the impact of expanding telemedicine services on appointment adherence, clinical outcomes, and financial reimbursement. Methods: This was a single-center, retrospective, quasi-experimental study of the impact of expanding telemedicine services on adult patients with diabetes, hypertension, and/or hyperlipidemia. The study included patients scheduled with a pharmacist at a hospital-based (HB) or physician-based (PB) clinic. The primary outcome was the difference in the mean no-show rate. The secondary outcomes were differences in mean change in HbA1c, LDL, blood pressure, and reimbursement. Mean differences between pre- and post-telemedicine groups of each clinic were measured for all outcomes. Results: The mean difference (SE) in the no-show rate in the HB clinic was -12.09% (4.862; P =.014), compared to 2.88% (3.656; P =.431) in the PB clinic. The mean difference (SE) in the change in HbA1c in the HB clinic was.00% (.338; P =.992), compared to.01% (.239; P =.945) in the PB clinic. The mean difference (SE) in reimbursement in the HB clinic was $1.93 (4.209; P =.647), compared to $20.46 (3.210; P